Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation

Lucie M. Turcotte, Tao Wang, Michael T. Hemmer, Stephen R. Spellman, Mukta Arora, Daniel Couriel, Amin Alousi, Joseph Pidala, Hisham Abdel-Azim, Ibrahim Ahmed, Amer Beitinjaneh, David Buchbinder, Michael Byrne, Natalie Callander, Nelson Chao, Sung Wong Choi, Zachariah Defilipp, Shahinaz M. Gadalla, Robert Peter Gale, Usama GergisShahrukh Hashmi, Peiman Hematti, Leona Holmberg, Yoshihiro Inamoto, Rammurti T. Kamble, Leslie Lehmann, Margaret A. MacMillan, Zachariah McIver, Taiga Nishihori, Maxim Norkin, Tracey O'Brien, Richard F. Olsson, Ran Reshef, Ayman Saad, Bipin N. Savani, Harry C. Schouten, Sachiko Seo, Melhem Solh, Leo Verdonck, Ravi Vij, Baldeep Wirk, Jean Yared, Mary M. Horowitz, Jennifer M. Knight, Michael R. Verneris

Research output: Contribution to journalArticlepeer-review

Original languageEnglish (US)
Pages (from-to)932-937
Number of pages6
JournalBone marrow transplantation
Volume53
Issue number7
DOIs
StatePublished - Jul 1 2018

Bibliographical note

Funding Information:
Acknowledgements This work was funded in part by the Children’s Cancer Research Fund, Minneapolis, MN (LMT) and the National Center for Advancing Translational Sciences (National Institutes of Health (NIH)) through Grant Numbers UL1TR001436 and KL2TR001438 (JMK). The CIBMTR is supported primarily by Public Health Service Grant/Cooperative Agreement 5U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 4U10HL069294 from NHLBI and NCI; a contract HHSH250201200016C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-17-1-2388 and N0014-17-1-2850 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals, Inc.; *Amgen, Inc.; *Amneal Biosciences; *Angiocrine Bioscience, Inc.; Anonymous donation to the Medical College of Wisconsin; Astellas Pharma US; Atara Biother-apeutics, Inc.; Be the Match Foundation; *bluebird bio, Inc.; *Bristol Myers Squibb Oncology; *Celgene Corporation; Cerus Corporation; *Chimerix, Inc.; Fred Hutchinson Cancer Research Center; Gamida Cell Ltd.; Gilead Sciences, Inc.; HistoGenetics, Inc.; Immucor; *Incyte Corporation; Janssen Scientific Affairs, LLC; *Jazz Pharmaceuticals, Inc.; Juno Therapeutics; Karyopharm Therapeutics, Inc.; Kite Pharma, Inc.; Medac, GmbH; MedImmune; The Medical College of Wisconsin; *Mediware; *Merck & Co, Inc.; *Mesoblast; MesoScale Diagnostics, Inc.; Millennium, the Takeda Oncology Co.; *Miltenyi Biotec, Inc.; National Marrow Donor Program; *Neovii Biotech NA, Inc.; Novartis Pharmaceuticals Corporation; Otsuka Pharmaceutical Co, Ltd.—Japan; PCORI; *Pfizer, Inc; *Pharmacyclics, LLC; PIRCHE AG; *Sanofi Genzyme; *Seattle Genetics; Shire; Spectrum Pharmaceuticals, Inc.; St. Baldrick’s Foundation; *Sunesis Pharmaceuticals, Inc.; Swedish Orphan Biovitrum, Inc.; Takeda Oncology; Telomere Diagnostics, Inc.; and University of Minnesota. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the U.S. Government. *Corporate Members Author contributions All listed authors participated in: (1) the conception and/or design of this study, data acquisition, and/or result interpretation; (2) drafting or revising the manuscript; and (3) approval of the final submitted manuscript. Dr. Turcotte has had full access to the data in the study and takes responsibility for the decision to submit for publication.

Cite this